Skip to content
Levaquin, Quinsair(levofloxacin)
Iquix, Levaquin, Quinsair, Quixin (levofloxacin) is a small molecule pharmaceutical. Levofloxacin was first approved as Levaquin on 1996-12-20. It is used to treat bacterial eye infections, bacterial infections, bacterial pneumonia, bacterial skin diseases, and bronchitis amongst others in the USA. It has been approved in Europe to treat cystic fibrosis and respiratory tract infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
eye diseasesD005128
urogenital diseasesD000091642
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levofloxacin
Tradename
Company
Number
Date
Products
LEVAQUINJohnson & JohnsonN-020634 DISCN1996-12-20
3 products, RLD
LEVAQUINJohnson & JohnsonN-020635 DISCN1996-12-20
1 products, RLD
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINERJohnson & JohnsonN-020635 DISCN1996-12-20
2 products, RLD
LEVAQUINJohnson & JohnsonN-020635 DISCN1996-12-20
1 products, RLD
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINERJohnson & JohnsonN-020635 DISCN1996-12-20
1 products, RLD
LEVAQUINJohnson & JohnsonN-021721 DISCN2004-10-21
1 products, RLD
QUIXINSantenN-021199 DISCN2000-08-18
1 products, RLD
IQUIXSantenN-021571 DISCN2004-03-01
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
levaquinANDA2016-05-26
levofloxacinANDA2023-06-07
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial eye infectionsD015818
bacterial infectionsD001424A49
bacterial pneumoniaEFO_1001272D018410J15.9
bacterial skin diseasesD017192
bronchitisD001991J40
chlamydia infectionsEFO_0007205D002690A74.9
escherichia coli infectionsEFO_1001318D004927B96.20
haemophilus infectionsEFO_1001127D006192
klebsiella infectionsEFO_1001353D007710
legionnaires' diseaseEFO_0007343D007877A48.1
Show 12 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
A02: Drugs for acid related disorders
A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
A02BD: Combinations for eradication of helicobacter pylori
A02BD10: Lansoprazole, amoxicillin and levofloxacin
J: Antiinfectives for systemic use
J01: Antibacterials for systemic use
J01M: Quinolone antibacterials
J01MA: Fluoroquinolone antibacterials, systemic
J01MA12: Levofloxacin
J01R: Combinations of antibacterials
J01RA: Combinations of antibacterials
J01RA05: Levofloxacin and ornidazole
S: Sensory organ drugs
S01: Ophthalmologicals
S01A: Antiinfective ophthalmologics
S01AE: Fluoroquinolone antiinfectives, ophthalmologic
S01AE05: Levofloxacin
HCPCS
Code
Description
J1956
Injection, levofloxacin, 250 mg
Clinical
Clinical Trials
263 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_00005441022739
Urinary tract infectionsD014552EFO_0003103N39.028616
Healthy volunteers/patients613111
PneumoniaD011014EFO_0003106J1828110
CataractD002386EFO_0001059H26.931149
Multidrug-resistant tuberculosisD018088EFO_00073814519
EndophthalmitisD00987733115
Pulmonary tuberculosisD014397EFO_1000049A151224
Pelvic inflammatory diseaseD000292EFO_1001388N70-N77224
Otitis mediaD010033EFO_0004992H66.9314
Show 27 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PyelonephritisD011704EFO_1001141N10-N16257
TuberculosisD014376EFO_0000774A15-A1922316
Hiv infectionsD015658EFO_0000764B202125
Chronic bronchitisD029481J42155
ProstatitisD011472EFO_0003830N41145
Diabetic footD017719EFO_1001459325
Bacterial infectionsD001424A49134
NeoplasmsD009369C80234
Cystic fibrosisD003550EFO_0000390E84224
Maxillary sinusitisD015523EFO_0007361J32.033
Show 45 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MyopiaD009216H52.11112
SarcoidosisD012507EFO_0000690D80-D8911
Non-hodgkin lymphomaD008228C85.911
PterygiumD011625H11.0111
Corneal diseasesD003316H18.9111
HyperopiaD006956H52.0111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pulmonary sarcoidosisD017565DOID_13406D86.011
Retinal diseasesD012164HP_0000479H35.911
Hearing lossD034381EFO_0004238H91.911
Escherichia coli infectionsD004927EFO_1001318B96.2011
Short bowel syndromeD01277811
PharmacokineticsD01059911
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SepsisD018805A41.922
MicrobiotaD06430711
Chemical and drug induced liver injuryD05648611
Refractive errorsD012030EFO_0003908H52.711
TherapeuticsD01381211
Helicobacter pyloriD016480NCBITaxon_210B96.8111
RadiotherapyD01187811
Drug-related side effects and adverse reactionsD064420T88.711
Drug monitoringD01690311
EpistaxisD004844EFO_0003895R04.011
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLEVOFLOXACIN
INNlevofloxacin
Description
Levofloxacin is an optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase. It has a role as a DNA synthesis inhibitor, an antibacterial drug, a topoisomerase IV inhibitor and an EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor. It is a quinolone antibiotic, a fluoroquinolone antibiotic and a 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid. It is an enantiomer of a dextrofloxacin.
Classification
Small molecule
Drug classantibacterials (quinolone derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
Identifiers
PDB
CAS-ID100986-85-4
RxCUI1546009
ChEMBL IDCHEMBL33
ChEBI ID63598
PubChem CID149096
DrugBankDB01137
UNII IDRIX4E89Y14 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Quinsair - Horizon Therapeutics Public
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 34,614 documents
View more details
Safety
Black-box Warning
Black-box warning for: Levofloxacin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
56,462 adverse events reported
View more details